Medicaid, ACA enrollment expected to decrease under One Big Beautiful Bill Act
The American Hospital Association has called passage of the One Big Beautiful Bill Act “an extremely disappointing and very difficult…
Payment decrease could be a ‘death knell’ for UnitedHealth, Amedisys deal
A managing director at financial services company Raymond James is questioning whether the recently proposed 6.4% payment decrease for home…
Integrity Concerns in Ticagrelor Trials Challenge Clinical Confidence
New findings question the integrity of ticagrelor’s clinical trials, raising safety concerns and impacting its use in cardiovascular care.
AI can help address provider time challenges
RhythmX AI reduces the amount of time providers spend on chart search and review, which allows them to focus on…
Episode 1041: Predicting Which Overdose Patients With Prolonged QTc Will Have Ventricular Dysrhythmia
Show notes at pharmacyjoe.com/episode1041. In this episode, I’ll discuss which overdose patients with prolonged QTc are most likely to experience…
Novo Nordisk Drops Hims & Hers: Inside the Compounded GLP-1 Crisis
GLP-1 medications like semaglutide face scrutiny over compounded versions, raising concerns about patient safety and counterfeit products in diabetes treatment.
Solving the Mental Health Gap with Prescription Digital Therapeutics
Prescription digital therapeutics (PDTs) offer scalable, accessible alternatives to traditional treatments—supporting patients, providers, and payers while addressing gaps in mental…
Elevated Remnant Cholesterol, Lp-PLA2 Linked to Heightened Risk of Composite Adverse Events
Stroke, myocardial infarction, and all-cause death were included in the composite of adverse cardiovascular events.
Hospitalized Adults With Community-Acquired Pneumonia Suffer Significant Morbidity Postdischarge
Six months following discharge from the hospital, adults who battled community-acquired pneumonia were at heightened risk of losing the ability…
Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product
Real-world data shows patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization.